These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 27679556)

  • 41. Endocannabinoids and Their Pharmacological Actions.
    Pertwee RG
    Handb Exp Pharmacol; 2015; 231():1-37. PubMed ID: 26408156
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging.
    Pascual AC; Gaveglio VL; Giusto NM; Pasquaré SJ
    Exp Gerontol; 2014 Jul; 55():134-42. PubMed ID: 24768821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
    Pryce G; Baker D
    Handb Exp Pharmacol; 2015; 231():213-31. PubMed ID: 26408162
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
    Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
    Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacology of cannabinoid CB1 and CB2 receptors.
    Pertwee RG
    Pharmacol Ther; 1997; 74(2):129-80. PubMed ID: 9336020
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The endocannabinoid-CB receptor system: Importance for development and in pediatric disease.
    Fride E
    Neuro Endocrinol Lett; 2004; 25(1-2):24-30. PubMed ID: 15159678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CB2 cannabinoid receptor mediation of antinociception.
    Ibrahim MM; Rude ML; Stagg NJ; Mata HP; Lai J; Vanderah TW; Porreca F; Buckley NE; Makriyannis A; Malan TP
    Pain; 2006 May; 122(1-2):36-42. PubMed ID: 16563625
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease.
    Javed H; Azimullah S; Haque ME; Ojha SK
    Front Neurosci; 2016; 10():321. PubMed ID: 27531971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors.
    Quartilho A; Mata HP; Ibrahim MM; Vanderah TW; Porreca F; Makriyannis A; Malan TP
    Anesthesiology; 2003 Oct; 99(4):955-60. PubMed ID: 14508331
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Crystal Structure of the Human Cannabinoid Receptor CB2.
    Li X; Hua T; Vemuri K; Ho JH; Wu Y; Wu L; Popov P; Benchama O; Zvonok N; Locke K; Qu L; Han GW; Iyer MR; Cinar R; Coffey NJ; Wang J; Wu M; Katritch V; Zhao S; Kunos G; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
    Cell; 2019 Jan; 176(3):459-467.e13. PubMed ID: 30639103
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.
    Janero DR; Makriyannis A
    Expert Opin Emerg Drugs; 2009 Mar; 14(1):43-65. PubMed ID: 19249987
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.
    Bagher AM; Laprairie RB; Kelly MEM; Denovan-Wright EM
    Methods Mol Biol; 2018; 1780():549-571. PubMed ID: 29856035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
    Pertwee RG
    Life Sci; 2005 Feb; 76(12):1307-24. PubMed ID: 15670612
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification and functional characterization of brainstem cannabinoid CB2 receptors.
    Van Sickle MD; Duncan M; Kingsley PJ; Mouihate A; Urbani P; Mackie K; Stella N; Makriyannis A; Piomelli D; Davison JS; Marnett LJ; Di Marzo V; Pittman QJ; Patel KD; Sharkey KA
    Science; 2005 Oct; 310(5746):329-32. PubMed ID: 16224028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Endocannabinoids drive the acquisition of an alternative phenotype in microglia.
    Mecha M; Feliú A; Carrillo-Salinas FJ; Rueda-Zubiaurre A; Ortega-Gutiérrez S; de Sola RG; Guaza C
    Brain Behav Immun; 2015 Oct; 49():233-45. PubMed ID: 26086345
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cannabinoid receptor agonists and antagonists stimulate insulin secretion from isolated human islets of Langerhans.
    Li C; Bowe JE; Huang GC; Amiel SA; Jones PM; Persaud SJ
    Diabetes Obes Metab; 2011 Oct; 13(10):903-10. PubMed ID: 21564460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence.
    Ibsen MS; Finlay DB; Patel M; Javitch JA; Glass M; Grimsey NL
    Front Pharmacol; 2019; 10():350. PubMed ID: 31024316
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases.
    Centonze D; Battistini L; Maccarrone M
    Curr Pharm Des; 2008; 14(23):2370-42. PubMed ID: 18781987
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Update on Non-CB
    Morales P; Reggio PH
    Cannabis Cannabinoid Res; 2017; 2(1):265-273. PubMed ID: 29098189
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protocol to Study β-Arrestin Recruitment by CB1 and CB2 Cannabinoid Receptors.
    Soethoudt M; van Gils N; van der Stelt M; Heitman LH
    Methods Mol Biol; 2016; 1412():103-11. PubMed ID: 27245896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.